| Fonds | 2026/Q1 | 2025/Q4 | 2025/Q3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | Investment ($) | QoQ ($) | QoQ (%) | |
| 224.190.634 $ | -133.788.202 $ | -36,1 % | 492.826.171 $ | +171.365.391 $ | +169,6 % | 146.255.232 $ | +68.583.244 $ | +89,6 % | |
| Janus Henderson Group Ltd. | 28.510.358 $ | -26.158.585 $ | -47,8 % | 54.668.943 $ | +14.176.182 $ | +35,0 % | 40.492.761 $ | +25.658.133 $ | +173,0 % |
| RA CAPITAL MANAGEMENT, L.P. | 28.700.000 $ | -20.950.000 $ | -42,2 % | 49.650.000 $ | |||||
| BlackRock, Inc. | 29.336.401 $ | -19.395.699 $ | -39,8 % | 48.732.100 $ | +34.316.049 $ | +238,0 % | |||
| Paradigm Biocapital Advisors LP | 35.496.929 $ | -11.801.627 $ | -25,0 % | 47.298.556 $ | |||||
| Vestal Point Capital, LP | 25.686.500 $ | -18.750.250 $ | -42,2 % | 44.436.750 $ | +22.856.750 $ | +105,9 % | |||
| Frazier Life Sciences Management, L.P. | 25.397.922 $ | -18.539.597 $ | -42,2 % | 43.937.519 $ | +14.557.345 $ | +49,5 % | 29.380.174 $ | +11.592.779 $ | +65,2 % |
| VANGUARD GROUP INC | 38.670.499 $ | +23.887.933 $ | +161,6 % | ||||||
| CITADEL ADVISORS LLC | 22.074.313 $ | -15.404.655 $ | -41,1 % | 37.478.968 $ | +12.784.522 $ | +51,8 % | 24.694.446 $ | +10.190.419 $ | +70,3 % |
| Avoro Capital Advisors LLC | 32.769.000 $ | ||||||||
| Affinity Asset Advisors, LLC | 28.988.211 $ | -2.787.789 $ | -8,8 % | 31.776.000 $ | +6.075.701 $ | +23,6 % | 25.700.299 $ | +11.271.092 $ | +78,1 % |
| Woodline Partners LP | 31.753.757 $ | +14.674.601 $ | +85,9 % | ||||||
| STATE STREET CORP | 31.654.079 $ | +28.036.308 $ | +775,0 % | ||||||
| BALYASNY ASSET MANAGEMENT L.P. | 25.987.552 $ | +9.870.821 $ | +61,2 % | ||||||
| 224.190.634 $ | -133.788.202 $ | -36,1 % | 492.826.171 $ | +171.365.391 $ | +169,6 % | 146.255.232 $ | +68.583.244 $ | +89,6 % | |